CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2013-- bluebird bio, Inc., a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced the closing of its initial public offering of 6,832,352 shares of common stock at an initial public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 891,176 additional shares of common stock. All of the shares in the offering were offered by bluebird bio. The company’s common stock is listed on The NASDAQ Global Select Market under the trading symbol “BLUE.”

J.P. Morgan Securities LLC and BofA Merrill Lynch are acting as joint book-running managers for the offering. Cowen and Company is acting as lead manager and Canaccord Genuity Inc. and Wedbush PacGrow Life Sciences are acting as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 18, 2013. Copies of the final prospectus relating to this offering may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (866) 803-9204, or from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at dg.prospectus_requests@baml.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Source: bluebird bio, Inc.

Investor Relations:
bluebird bio, Inc.
Richard E. T. Smith, Ph.D., 617-588-3321
rsmith@bluebirdbio.com
or
Media Contact:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com